Literature DB >> 31827018

Cupid and Psyche system for the diagnosis and treatment of advanced cancer.

Akira Sugiyama1,2, Takeshi Kawamura1,2, Toshiya Tanaka1, Hirofumi Doi1, Takefumi Yamashita1, Keiko Shinoda1, Hideaki Fujitani1, Kenzo Yamatsugu3, Yohei Shimizu3, Toshifumi Tatsumi3, Kazuki Takahashi3, Motomu Kanai3, Eiichi Mizohata4, Tatsuya Kawato4, Takefumi Doi5, Tsuyoshi Inoue5, Tatsuhiko Kodama1.   

Abstract

In advanced cancer patients, malignant cells invade and disseminate within normal cells and develop resistance to therapy with additional genetic mutations, which makes radical cure very difficult. Precision medicine against advanced cancer is hampered by the lack of systems aimed at multiple target molecules within multiple loci. Here, we report the development of a versatile diagnostic and therapeutic system for advanced cancer, named the Cupid and Psyche system. Based on the strong non-covalent interaction of streptavidin and biotin, a low immunogenic mutated streptavidin, Cupid, and a modified artificial biotin, Psyche, have been designed. Cupid can be fused with various single-chain variable fragment antibodies and forms tetramer to recognize cancer cells precisely. Psyche can be conjugated to a wide range of diagnostic and therapeutic agents against malignant cells. The Cupid and Psyche system can be used in pre-targeting therapy as well as photo-immunotherapy effectively in animal models supporting the concept of a system for precision medicine for multiple targets within multiple loci.

Entities:  

Keywords:  cancer; monoclonal antibody; photo-immunotherapy; pre-targeting; theranostics

Mesh:

Substances:

Year:  2019        PMID: 31827018      PMCID: PMC6920082          DOI: 10.2183/pjab.95.041

Source DB:  PubMed          Journal:  Proc Jpn Acad Ser B Phys Biol Sci        ISSN: 0386-2208            Impact factor:   3.493


  18 in total

1.  Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C.

Authors:  Christilyn P Graff; Kerry Chester; Richard Begent; K Dane Wittrup
Journal:  Protein Eng Des Sel       Date:  2004-04-28       Impact factor: 1.650

2.  Mapping the common antigenic determinants in avidin and streptavidin.

Authors:  N Subramanian; P R Adiga
Journal:  Biochem Mol Biol Int       Date:  1997-10

Review 3.  Radioimmunotherapy of human tumours.

Authors:  Steven M Larson; Jorge A Carrasquillo; Nai-Kong V Cheung; Oliver W Press
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

4.  A new initiative on precision medicine.

Authors:  Francis S Collins; Harold Varmus
Journal:  N Engl J Med       Date:  2015-01-30       Impact factor: 91.245

Review 5.  Strategies and challenges for the next generation of antibody-drug conjugates.

Authors:  Alain Beck; Liliane Goetsch; Charles Dumontet; Nathalie Corvaïa
Journal:  Nat Rev Drug Discov       Date:  2017-03-17       Impact factor: 84.694

6.  Mutations for decreasing the immunogenicity and maintaining the function of core streptavidin.

Authors:  Kyohei Yumura; Mihoko Ui; Hirofumi Doi; Takao Hamakubo; Tatsuhiko Kodama; Kouhei Tsumoto; Akira Sugiyama
Journal:  Protein Sci       Date:  2013-01-04       Impact factor: 6.725

7.  Assessment of biotin status: clinical implications.

Authors:  H Baker
Journal:  Ann N Y Acad Sci       Date:  1985       Impact factor: 5.691

Review 8.  Unravelling biology and shifting paradigms in cancer with single-cell sequencing.

Authors:  Timour Baslan; James Hicks
Journal:  Nat Rev Cancer       Date:  2017-08-24       Impact factor: 60.716

9.  A sensitive and practical competitive radioassay for plasma biotin.

Authors:  Catherine Harthé; Bruno Claustrat
Journal:  Ann Clin Biochem       Date:  2003-05       Impact factor: 2.057

10.  Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules.

Authors:  Makoto Mitsunaga; Mikako Ogawa; Nobuyuki Kosaka; Lauren T Rosenblum; Peter L Choyke; Hisataka Kobayashi
Journal:  Nat Med       Date:  2011-11-06       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.